e-Profile Login and ID Quick Search
New Jersey News: New Jersey Senate Bill 1604
Reprinted form the April 2008 New Jersey Board of Pharmacy Newsletter.
New Jersey Senate Bill 1604, signed by Governor Jon Corzine on January 4, 2008, amends the New Jersey Controlled Dangerous Substances Act to allow the use of electronic order forms (commonly known as 222 forms) in New Jersey. Section 14 of P.L.1970, c.226 (C.24:21-14) is entitled “Order Forms.” As amended, C.24:21-14(d) reads: “Use of an official written order in electronic form shall comply with the requirements of State law and regulations.” The use of electronic ordering took effect immediately.
This bill also establishes new requirements for New Jersey Prescription Blanks. As amended, Section 20 of P.L.2003, c.280 (C.45:14-59) reads in part:
The Division of Consumer Affairs in the Department of Law and Public Safety shall establish the format for uniform, non-reproducible, non-erasable safety paper prescription blanks, to be known as New Jersey Prescription Blanks, which format shall include an identifiable logo or symbol that will appear on all prescription blanks. The prescription blanks for each practitioner or health care facility shall be numbered consecutively and if the prescriber or health care facility has a National Provider Identifier, the prescription blank shall include the National Provider Identifier.
The use of the new New Jersey Prescription Blanks with the consecutive numbering and the National Provider Identifier will go into effect on October 1, 2008.
In addition to the above changes, this bill moved the responsibility for oversight of controlled substances from the Department of Health and Senior Services to the Division of Consumer Affairs in the Department of Law and Public Safety and established a Prescription Monitoring Program, which will consist of an electronic system for monitoring controlled dangerous substances that are dispensed in or into the state by a pharmacist in an outpatient setting. We will include information regarding the Prescription Monitoring Program in future Newsletters as the Division of Consumer Affairs develops this program.
